First Quarter 2026 and Recent Corporate Updates • First-quarter 2026 Rezdiffra (resmetirom) net sales of $311.3 million, representing year-over-year growth of 127% ® • As of March 31, 2026, more than 42,250 patients on Rezdiffra, up 2.5x from 1Q25, reflecting continued strong physician adoption and high patient demand • Advances pipeline with global licensing agreement for a clinical-stage siRNA asset targeting a mutation in the PNPLA3 gene, a genetically validated driver of MASH • MGL-2086 (oral GLP-1) Pha ...